Dr. Levy on EGFR TKIs in Lung Cancer

Benjamin P. Levy, MD
Published: Monday, Nov 09, 2015



Benjamin P. Levy, MD, medical director, Thoracic Oncology, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

More agents have been approved in the field for patients with EGFR mutations within the past year, Levy explains, such as gefitinib. Prior to such approvals, treatment choices included erlotinib and afatinib. The combination of erlotinib plus bevacizumab is also being investigated in an ongoing US study.

There are also third-generation TKIs previously used for resistant disease that are now being studied in the frontline setting, Levy says.

<<< View more from the 2015 NY Lung Cancer Symposium



Benjamin P. Levy, MD, medical director, Thoracic Oncology, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

More agents have been approved in the field for patients with EGFR mutations within the past year, Levy explains, such as gefitinib. Prior to such approvals, treatment choices included erlotinib and afatinib. The combination of erlotinib plus bevacizumab is also being investigated in an ongoing US study.

There are also third-generation TKIs previously used for resistant disease that are now being studied in the frontline setting, Levy says.

<<< View more from the 2015 NY Lung Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x